describ
normal
pregnanc
outcom
case
first
trimest
exposur
inject
ribavirin
pregnant
woman
receiv
three
intramuscular
inject
ribavirin
suspect
sar
deliv
week
gestat
healthi
babi
girl
pediatr
follow
month
age
physic
examin
neurodevelopment
mileston
normal
ribavirin
broad
spectrum
nucleosid
analogu
efficaci
treatment
sever
viral
infect
commonli
use
treatment
respiratori
syncyti
viru
rsv
infect
ribavirin
exert
antivir
effect
inhibit
inosin
monophosph
dehydrogenas
inhibit
enzym
prevent
biosynthesi
guanin
nucleotid
interfer
dna
rna
replic
abil
obstruct
biosynthes
guanin
nucleotid
ribavirin
treatment
pregnanc
specif
first
trimest
may
potenti
interfer
embryon
develop
ribavirin
exhibit
two
stage
elimin
rel
short
plasma
halflif
h
follow
longer
termin
halflif
h
due
slow
releas
activ
metabolit
ribavirin
triphosph
erythrocyt
adult
oral
dose
mg
ribavirin
yield
peak
plasma
concentr
mcgml
bioavail
intraven
dose
mg
result
mean
concentr
mcgml
wherea
aerosol
prepar
yield
serum
concentr
mcgml
contrast
ribavirin
level
respiratori
secret
higher
follow
secondari
aerosol
drug
exposur
health
care
worker
inhal
system
absorb
dose
would
less
oral
therapeut
dose
recent
sever
acut
respiratori
syndrom
sar
outbreak
ribavirin
use
variou
countri
novel
coronaviru
initi
report
note
improv
surrog
marker
outcom
resolut
fever
improv
oxygen
radiograph
appear
ribavirin
dose
recommend
treatment
sar
mg
intraven
iv
everi
h
day
mg
oral
twice
daili
day
although
larg
variat
dose
regimen
differ
institut
preclin
studi
pregnant
rodent
use
dose
within
human
therapeut
rang
produc
teratogen
effect
depend
dose
time
exposur
frequenc
skelet
malform
increas
significantli
among
offspr
pregnant
mice
expos
ribavirin
dose
time
use
human
malform
seen
among
surviv
offspr
rabbit
pregnant
rabbit
treat
oral
ribavirin
dose
smaller
use
human
increas
rate
embryon
fetal
death
anoth
studi
treatment
seven
pregnant
baboon
dose
three
six
time
larger
human
oral
dose
result
teratogen
known
whether
ribavirin
caus
similar
harm
human
concern
regard
potenti
teratogen
women
childbear
age
secondari
exposur
aerosol
ribavirin
studi
eg
nurs
mother
sever
investig
collect
blood
urin
specimen
health
care
worker
volunt
expos
aerosol
ribavirin
assess
potenti
exposur
environment
ribavirin
three
studi
suggest
secondari
absorpt
ribavirin
health
care
worker
occur
minim
although
toxic
advers
effect
ribavirin
aerosol
observ
particip
percept
teratogen
risk
anxieti
often
high
date
publish
report
relat
ribavirin
exposur
first
trimest
pregnanc
report
nine
pregnant
women
treat
ribavirin
second
half
pregnanc
sever
measl
infect
eight
women
receiv
therapi
day
via
facemask
one
woman
receiv
therapi
day
via
endotrach
tube
infant
healthi
advers
effect
commun
outbreak
sar
hong
kong
five
live
born
infant
born
pregnant
women
sar
receiv
ribavirin
late
pregnanc
five
mother
receiv
iv
ribavirin
acut
phase
diseas
subsequ
two
newborn
receiv
ribavirin
iv
part
manag
well
three
mother
deliv
babi
shortli
receiv
ribavirin
two
ribavirin
week
continu
pregnanc
deliv
healthi
babi
week
woman
travel
china
sar
outbreak
time
awar
week
pregnant
stay
china
develop
cold
cough
symptom
seen
physician
advis
receiv
total
six
inject
mg
ribvirin
intramuscularli
im
daili
three
day
eventu
receiv
total
three
inject
mg
im
ribavirin
within
period
recal
receiv
medic
besid
ribavirin
possibl
sar
case
rule
investig
cold
symptom
subsid
continu
pregnanc
without
complic
week
pregnanc
call
motherisk
order
get
inform
regard
ribavirin
exposur
possibl
advers
effect
current
pregnanc
sent
ultrasound
us
week
pregnanc
report
within
normal
rang
age
underw
amniocentesi
week
pregnanc
neg
result
pregnanc
continu
unev
develop
contract
week
assist
induct
deliv
babi
girl
normal
apgar
score
birth
weight
kg
lb
oz
babi
need
specif
medic
attent
well
hospit
stay
babi
discharg
hospit
h
newborn
develop
mild
jaundic
postnat
day
necessit
treatment
subsid
day
accord
matern
report
babi
month
old
healthi
state
child
follow
pediatrician
sinc
birth
last
seen
pediatrician
month
age
report
infant
pediatrician
physic
examin
complet
normal
evid
malform
minor
anomali
abl
sit
straight
without
support
babbl
central
grasp
month
age
pediatrician
also
confirm
neurodevelopment
mileston
within
normal
rang
mother
express
concern
regard
growth
health
babi
time
follow
interview
sever
acut
respiratori
syndrom
highli
infecti
diseas
high
rate
morbid
mortal
major
therapeut
modal
treatment
empir
critic
affect
pregnant
women
treat
potenti
teratogen
drug
commonli
use
firstlin
medic
outbreak
ribavirin
corticosteroid
ribavirin
fda
pregnanc
categori
x
indic
high
teratogen
probabl
base
consist
anim
studi
biolog
plausibl
henc
drug
contraind
women
may
becom
pregnant
use
ribavirin
consid
critic
physician
pregnant
patient
made
awar
potenti
teratogen
effect
ribavirin
limit
inform
use
human
pregnanc
concern
teratogen
higher
first
trimest
organogenesi
ribavirin
may
theoret
also
caus
function
defect
even
first
trimest
manufactur
schere
corp
http
wwwribavirinpregnancyregistrycom
maintain
registri
pregnancyrel
exposur
advis
women
wait
month
follow
discontinu
ribavirin
attempt
get
pregnant
follow
inject
matern
system
exposur
ribavirin
higher
follow
secondari
exposur
aerosol
drug
despit
ribavirin
introduc
system
first
trimest
caus
congenit
abnorm
development
defect
infant
although
report
limit
describ
singl
case
best
knowledg
first
descript
system
matern
exposur
embryogenesi
